-
Neurocrine Biosciences Initiates Phase 3 Registrational Program For NBI-1117568 As Potential Treatment For Adults With Schizophrenia
30 Apr 2025 15:55 GMT
(MENAFN- PR Newswire)
SAN DIEGO, April 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced the initiation of a Phase 3 registrational program to evaluate the efficacy, safety and tolerability of NBI-1117568, the …
-
The Analyst Verdict: WAVE Life Sciences In The Eyes Of 4 Experts
29 Apr 2025 22:31 GMT
4 analysts have expressed a variety of opinions on WAVE Life Sciences WVE over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments …
-
Valbenazine Safe and Effective for Long-Term Treatment of Tardive Dyskinesia in Elders
29 Apr 2025 17:55 GMT
A published paper pooling the 48-week KINECT-3 extension (NCT02274558) and KINECT-4 (NCT02405091) studies of valbenazine (Ingrezza; Neurocrine Biosciences) revealed that the therapy was safe and effective for elderly patients with tardive dyskinesia (TD) …
-
Prilenia signs deal for former Teva ALS drug worth up to €500m
29 Apr 2025 15:41 GMT
Israeli-Dutch clinical stage biotech company Prilenia Therapeutics has announced a collaboration and licensing agreement for its lead drug Pridopidine, with Spanish pharmaceutical company Ferrer. As part of the agreement Prilenia will receive €125 million …
-
ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
28 Apr 2025 21:05 GMT
– Oral and poster presentations will highlight advancements from ElevateBio’s two business units: Life Edit, its gene editing and R&D technology business, and BaseCamp®, its process development and cGMP manufacturing business – ElevateBio's …
-
Expanding What We Know About Autism Genetics
28 Apr 2025 14:25 GMT
A rare disorder called myotonic dystrophy type 1 (DM1) causes weakness and muscle loss that gets progressively worse. Patients with DM1 are about 14 times more likely to be diagnosed with autism spectrum disorder compared to the general population. …
-
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets
28 Apr 2025 05:08 GMT
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it …
-
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine
28 Apr 2025 05:08 GMT
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V., a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement …
-
House Once Gave Foreman An Amazing Storyline (Then Forgot About It)
26 Apr 2025 20:28 GMT
While House is widely regarded as one of the best TV dramas of all time, the show occasionally forgot major storylines, leaving them unresolved. The members of Dr. Gregory House's diagnostics team all had problems of their own outside of work, and …
-
Dementia in Younger People Is Often Overlooked. Here Are 5 Key Reasons.
26 Apr 2025 03:46 GMT
Around 57 million people worldwide have dementia. While most cases of dementia are diagnosed in older adults, about 7% of cases occur in people under 65.
This number may be even higher as young-onset dementia continues to be under-recognised. This means …
About
© 1995-2025